🟢 Adaptive Biotechnologies is trading 4.7% up in pre-market amid broad risk-on sentiment

Adaptive Biotechnologies is trading 4.7% higher at $29.97, primarily in line with broader risk-on sentiment rather than a fresh company-specific catalyst.

• The stock closed at $28.61 on September 18 after a strong recent advance, while major U.S. indexes are also higher in pre-market trading.
• No new company announcement dated September 21 was identified; the latest release, on September 17, highlighted stronger NCCN recommendations for MRD testing and referenced clonoSEQ®.
• Trading volume and activity levels were unavailable.